-
ACS Nano Mar 2024Extracellular vesicles (EVs) are natural lipid nanoparticles secreted by most types of cells. In malignant cancer, EVs derived from cancer cells contribute to its... (Review)
Review
Extracellular vesicles (EVs) are natural lipid nanoparticles secreted by most types of cells. In malignant cancer, EVs derived from cancer cells contribute to its progression and metastasis by facilitating tumor growth and invasion, interfering with anticancer immunity, and establishing premetastasis niches in distant organs. In recent years, multiple strategies targeting cancer-derived EVs have been proposed to improve cancer patient outcomes, including inhibiting EV generation, disrupting EVs during trafficking, and blocking EV uptake by recipient cells. Developments in EV engineering also show promising results in harnessing cancer-derived EVs as anticancer agents. Here, we summarize the current understanding of the origin and functions of cancer-derived EVs and review the recent progress in anticancer therapy targeting these EVs.
Topics: Humans; Neoplasms; Extracellular Vesicles; Antineoplastic Agents; Biological Transport
PubMed: 38393984
DOI: 10.1021/acsnano.3c06462 -
Current Medicinal Chemistry 2018
Topics: Antineoplastic Agents; Biological Products; Cell Proliferation; Fungi; Humans; Neoplasms
PubMed: 29378503
DOI: 10.2174/092986732502180122153435 -
Trends in Pharmacological Sciences Jun 2024
Topics: Humans; Neoplasms; Drug Resistance, Neoplasm; Antineoplastic Agents
PubMed: 38777669
DOI: 10.1016/j.tips.2024.05.002 -
Carbohydrate Polymers Sep 2023Platinum anticancer drugs have been explored and developed in recent years to reduce systematic toxicities and resist drug resistance. Polysaccharides derived from... (Review)
Review
Platinum anticancer drugs have been explored and developed in recent years to reduce systematic toxicities and resist drug resistance. Polysaccharides derived from nature have abundant structures as well as pharmacological activities. The review provides insights on the design, synthesis, characterization and associating therapeutic application of platinum complexes with polysaccharides that are classified by electronic charge. The complexes give birth to multifunctional properties with enhanced drug accumulation, improved tumor selectivity and achieved synergistic antitumor effect in cancer therapy. Several techniques developing polysaccharides-based carriers newly are also discussed. Moreover, the lasted immunoregulatory activities of innate immune reactions triggered by polysaccharides are summarized. Finally, we discuss the current shortcomings and outline potential strategies for improving platinum-based personalized cancer treatment. Using platinum-polysaccharides complexes for improving the immunotherapy efficiency represents a promising framework in future.
Topics: Humans; Platinum; Precision Medicine; Neoplasms; Antineoplastic Agents
PubMed: 37230639
DOI: 10.1016/j.carbpol.2023.120997 -
Nature Biomedical Engineering Aug 2018
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Design; Humans; Immunotherapy; Neoplasms
PubMed: 31015638
DOI: 10.1038/s41551-018-0283-1 -
Drug Discovery Today Sep 2014Inhibitors of epigenetic targets have entered clinical trials with some success, in particular for combined therapies. Like many other chemotherapeutics these new... (Review)
Review
Inhibitors of epigenetic targets have entered clinical trials with some success, in particular for combined therapies. Like many other chemotherapeutics these new classes of molecules have dose-limiting toxicities and highly active metabolism in vivo resulting in lower efficacy than expected. This review presents drug delivery strategies proposed to prolong epigenetic inhibitor effects while reducing toxicities and metabolic clearance. Inspired from the work done in cancer-targeted strategies, prodrugs and nanoparticle-based drug delivery systems are discussed in a comprehensive way, detailing the chemical and physiological principles of the selected releasing method and, when available, how epigenetic chemistry can be exploited.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Design; Epigenesis, Genetic; Humans; Nanoparticles; Neoplasms; Prodrugs
PubMed: 24680930
DOI: 10.1016/j.drudis.2014.03.017 -
Cardiology in Review 2019Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites, and alkylating... (Review)
Review
Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites, and alkylating agents is well known, it is important to realize that newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are also associated with significant adverse cardiovascular effects. Echocardiography, magnetic resonance imaging, and radionuclide imaging have been used to identify these complications early and prevent further consequences. We will discuss the different classes of cancer therapeutic agents that cause cardiotoxicity, the mechanisms that lead to these effects, and strategies that can be used to prevent the cardiac morbidity and mortality associated with their use.
Topics: Antineoplastic Agents; Cardiotoxicity; Female; Humans; Male; Neoplasms
PubMed: 30433897
DOI: 10.1097/CRD.0000000000000239 -
Nanoscale Nov 2023Camptothecin (CPT) is a cytotoxic alkaloid that attenuates the replication of cancer cells blocking DNA topoisomerase 1. Despite its encouraging and wide-spectrum... (Review)
Review
Camptothecin (CPT) is a cytotoxic alkaloid that attenuates the replication of cancer cells blocking DNA topoisomerase 1. Despite its encouraging and wide-spectrum antitumour activity, its application is significantly restricted owing to its instability, low solubility, significant toxicity, and acquired tumour cell resistance. This has resulted in the development of many CPT-based therapeutic agents, especially CPT-based nanomedicines, with improved pharmacokinetic and pharmacodynamic profiles. Specifically, smart CPT-based prodrug nanomedicines with stimuli-responsive release capacity have been extensively explored owing to the advantages such as high drug loading, improved stability, and decreased potential toxicity caused by the carrier materials in comparison with normal nanodrugs and traditional delivery systems. In this review, the potential strategies and applications of CPT-based nanoprodrugs for enhanced CPT delivery toward cancer cells are summarized. We appraise in detail the chemical structures and release mechanisms of these nanoprodrugs and guide materials chemists to develop more powerful nanomedicines that have real clinical therapeutic capacities.
Topics: Prodrugs; Drug Delivery Systems; Camptothecin; Nanomedicine; Antineoplastic Agents; Cell Line, Tumor; Nanoparticles; Neoplasms
PubMed: 37909755
DOI: 10.1039/d3nr04147f -
Current Pharmaceutical Design 2018The oncology pharmaceutical research spent a shocking amount of money on target validation and drug optimization in preclinical models because many oncology drugs fail... (Review)
Review
The oncology pharmaceutical research spent a shocking amount of money on target validation and drug optimization in preclinical models because many oncology drugs fail during clinical trial phase III. One of the most important reasons for oncology drug failures in clinical trials may due to the poor predictive tool of existing preclinical models. Therefore, in cancer research and personalized medicine field, it is critical to improve the effectiveness of preclinical predictions of the drug response of patients to therapies and to reduce costly failures in clinical trials. Three dimensional (3D) tumor models combine micro-manufacturing technologies mimic critical physiologic parameters present in vivo, including complex multicellular architecture with multicellular arrangement and extracellular matrix deposition, packed 3D structures with cell-cell interactions, such as tight junctions, barriers to mass transport of drugs, nutrients and other factors, which are similar to in vivo tumor tissues. These systems provide a solution to mimic the physiological environment for improving predictive accuracy in oncology drug discovery. This review gives an overview of the innovations, development and limitations of different types of tumor-like construction techniques such as self-assemble spheroid formation, spheroids formation by micro-manufacturing technologies, micro-dissected tumor tissues and tumor organoid. Combination of 3D tumor-like construction and microfluidic techniques to achieve tumor on a chip for in vitro tumor environment modeling and drug screening were all included. Eventually, developmental directions and technical challenges in the research field are also discussed. We believe tumor on chip models have provided better sufficient clinical predictive power and will bridge the gap between proof-of-concept studies and a wider implementation within the oncology drug development for pathophysiological applications.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Lab-On-A-Chip Devices; Neoplasms
PubMed: 30727877
DOI: 10.2174/1381612825666190206235233 -
Molecules (Basel, Switzerland) Mar 2021It has been an absolute pleasure to be the guest editor of this Special Issue! As the title indicates, the topic is on the advances made against cancer [...].
It has been an absolute pleasure to be the guest editor of this Special Issue! As the title indicates, the topic is on the advances made against cancer [...].
Topics: Antineoplastic Agents; Drug Discovery; Humans; Neoplasms
PubMed: 33804936
DOI: 10.3390/molecules26071821